Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.47
-1.3%
$3.17
$1.10
$106.04
$2.81M-1.67277,974 shs149,952 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$3.36
+28.2%
$2.64
$1.72
$15.70
$4.06M0.21243,589 shs3.09 million shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$0.00
$710K-0.21134,354 shs1.00 million shs
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
$0.33
-1.5%
$0.54
$8.05
$15.80
$2.53M0.057,755 shs502,785 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRI Bio, Inc. stock logo
GRI
GRI Bio
-3.87%-21.99%+12.03%-84.06%-98.35%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
+14.91%-6.76%-4.38%-18.13%-50.23%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%-66.67%0.00%0.00%
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
-7.43%-2.94%-44.07%-97.36%-97.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GRI Bio, Inc. stock logo
GRI
GRI Bio
2.723 of 5 stars
3.54.00.00.02.60.01.3
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.7638 of 5 stars
0.05.00.00.01.80.00.6
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GRI Bio, Inc. stock logo
GRI
GRI Bio
3.00
Buy$115.507,757.14% Upside
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.00
N/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NPHC, INM, GRI, and PWUP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/14/2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/AN/AN/AN/A$5.22 per shareN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.83M0.84N/AN/A$5.12 per share0.66
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$13.04M-$11.56N/AN/AN/AN/A-289.05%-165.01%5/16/2025 (Estimated)
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$7.68M-$13.75N/AN/A-163.75%-90.74%-71.70%N/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A

Latest NPHC, INM, GRI, and PWUP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/16/2025Q1 2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$4.08N/AN/AN/AN/AN/A
5/12/2025Q3 2025
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A-$1.94N/A-$1.94N/A$1.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.91129.93%N/AN/A N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/A
3.10
3.10
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.09
3.05
2.44
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
GRI Bio, Inc. stock logo
GRI
GRI Bio
33.95%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
19.17%

Insider Ownership

CompanyInsider Ownership
GRI Bio, Inc. stock logo
GRI
GRI Bio
0.13%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.85%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
48.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
GRI Bio, Inc. stock logo
GRI
GRI Bio
11.91 million8.92 millionNot Optionable
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
101.21 million711,000Not Optionable
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/A7.77 million4.04 millionNot Optionable

Recent News About These Companies

Aspire Biopharma, PowerUp Acquisition complete business combination
Aspire Biopharma announces public listing on Nasdaq
(PWUP) Technical Pivots with Risk Controls
PowerUp Acquisition Corp trading resumes
PowerUp Acquisition Corp trading halted, volatility trading pause
When (PWUP) Moves Investors should Listen
PowerUp Acquisition Corp. Cl A
How to Take Advantage of moves in (PWUP)
PWUP PowerUp Acquisition Corp.
How To Trade (PWUP)
When the Price of (PWUP) Talks, People Listen
(PWUPU) Investment Analysis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
GRI Bio stock logo

GRI Bio NASDAQ:GRI

$1.47 -0.02 (-1.34%)
As of 04:00 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$3.36 +0.74 (+28.24%)
As of 04:00 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

$0.0001 0.00 (0.00%)
As of 01:10 PM Eastern

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

PowerUp Acquisition stock logo

PowerUp Acquisition NASDAQ:PWUP

$0.33 0.00 (-1.45%)
As of 05/13/2025

PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York.